Evidence map›Paper›PMID 42290675›Full record

ArticleNeurology. Genetics2026

Loss of SARM1 Improves Phenotypes in a Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Papa Serigne Ndiaye, Sharan Paul, Guoli Zhao, Chen Ding, Stefan M Pulst, Thomas Schwarz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Papa Serigne NdiayeF.M. Kirby Neurobiology Center, Boston Children's Hospital, MA.ORCID https://orcid.org/0009-0006-7914-7436
Sharan PaulDepartment of Neurology, University of Utah, Salt Lake City; and.ORCID https://orcid.org/0000-0002-9845-3125
Guoli ZhaoF.M. Kirby Neurobiology Center, Boston Children's Hospital, MA.ORCID https://orcid.org/0000-0002-7807-5980
Chen DingF.M. Kirby Neurobiology Center, Boston Children's Hospital, MA.ORCID https://orcid.org/0000-0002-1054-9668
Stefan M PulstDepartment of Neurology, University of Utah, Salt Lake City; and.ORCID https://orcid.org/0000-0003-0883-7879
Thomas SchwarzF.M. Kirby Neurobiology Center, Boston Children's Hospital, MA.ORCID https://orcid.org/0000-0001-7532-0250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease caused by pathogenic variants in Methods: We studied 4 cohorts of mice: (1) Results: Probing of cerebellar extracts showed that the Purkinje cell protein markers Calbindin-1, RGS8, and PCP2 were decreased in Discussion: We conclude that SARM1 contributes to neurodegeneration in ARSACS, and its downregulation or inhibition could constitute a significant therapeutical strategy in the treatment of the disease.

Identifiers

PMID42290675
PMCPMC13262670

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.